← Back to Search

Anti-fibrotic agent

AP01 for Pulmonary Fibrosis

Phase 2
Recruiting
Research Sponsored by Avalyn Pharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Worsening respiratory symptoms with no alternative explanation
Radiological evidence of disease progression including increased extent or severity of traction bronchiectasis and bronchiolectasis, new ground-glass opacity with traction bronchiectasis, new fine reticulation, increased extent or increased coarseness of reticular abnormality, new or increased honeycombing, increased lobar volume loss
Must not have
Diagnosis of idiopathic pulmonary fibrosis (IPF) based on the ATS diagnostic algorithm for IPF
Current treatment with oral pirfenidone within 3 months prior to Screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52
Awards & highlights

Summary

This trial will test whether a new drug, AP01, is safe and effective in treating a specific condition when added to standard treatment. Participants will receive either AP01 or a placebo for 52 weeks

Who is the study for?
This trial is for people with Progressive Pulmonary Fibrosis who have worsening respiratory symptoms, an FVC of at least 45%, and a DLCO of at least 30%. Those on nintedanib must meet specific criteria related to their treatment duration and stability. Participants need to be able to perform acceptable spirometry tests.Check my eligibility
What is being tested?
The study is testing the safety and effectiveness of two doses of AP01 compared to a placebo in addition to standard care over one year. It's randomized, meaning participants are put into groups by chance, double-blind so neither they nor the researchers know who gets what, and placebo-controlled for comparison.See study design
What are the potential side effects?
While not specified here, common side effects in trials like this may include gastrointestinal issues (like nausea or diarrhea), skin reactions (rash or itching), fatigue, coughing or shortness of breath that could worsen existing conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breathing problems are getting worse without any other known cause.
Select...
My lung scans show worsening or new signs of lung damage.
Select...
My lung function tests meet the required levels.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with IPF according to the ATS guidelines.
Select...
I have been taking pirfenidone in the last 3 months.
Select...
My kidney function is low, with a creatinine clearance under 30 mL/min.
Select...
My liver tests are abnormal.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)
Secondary outcome measures
To evaluate the change from baseline in quantitative lung fibrosis score.
To evaluate the effect of AP01 high dose and AP01 low dose compared to placebo on disease progression (defined as absolute FVC percent predicted decline of ≥10% prior to Week 52)
To evaluate the effect of AP01 high dose, AP01 low dose compared to placebo on quality of life (QoL)
Other outcome measures
To evaluate the safety of AP01 high dose and AP01 low dose compared to placebo

Side effects data

From 2019 Phase 3 trial • 60 Patients • NCT03208933
27%
Nausea
22%
Decreased appetite
13%
Dyspepsia
13%
Vomiting
12%
Diarrhoea
10%
Dyspnoea
7%
Cough
7%
Pruritus
7%
Weight decreased
3%
Idiopathic pulmonary fibrosis
3%
Death
2%
Atrial fibrillation
2%
Bronchitis chronic
2%
Sudden cardiac death
2%
Pneumonia
2%
Cholecystitis infective
2%
Bronchitis bacterial
2%
Adenocarcinoma of colon
2%
Atrial flutter
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pirfenidone

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: AP01 Low Dose BIDExperimental Treatment1 Intervention
Pirfenidone Solution for Inhalation
Group II: AP01 High Dose BIDExperimental Treatment1 Intervention
Pirfenidone Solution for Inhalation
Group III: Placebo BIDPlacebo Group1 Intervention
Placebo solution for inhalation

Find a Location

Who is running the clinical trial?

Avalyn Pharma Inc.Lead Sponsor
DevPro BiopharmaUNKNOWN
2 Previous Clinical Trials
219 Total Patients Enrolled
1 Trials studying Pulmonary Fibrosis
135 Patients Enrolled for Pulmonary Fibrosis
Avalyn Pharma, Inc.Study DirectorAvalyn Pharma Inc.
~200 spots leftby Apr 2026